Tailored Therapy Versus Empiric Chosen Treatment for *Helicobacter pylori* Eradication

A Meta-Analysis

Han Chen, MD, Yini Dang, MD, PhD, Xiaoying Zhou, MD, PhD, Bingtuan Liu, MD, PhD, Shiyu Liu, MD, PhD, and Guoxin Zhang, MD, PhD

Abstract: Although various regimens are empirically accepted for *Helicobacter pylori* eradication, the efficacy might be declined by multiple individual factors. The necessity of a personalized eradication therapy still remains controversial. The aim of the study was to compare tailored therapy with empiric chosen regimens.

Databases of PUBMED, EMBASE, and MEDLINE were searched for eligible studies, published up to October 2015. All relevant controlled clinical trials were included. A random-effect model was applied to compare pooled relative risk (RR) with related 95% confidence intervals (CIs).

Thirteen controlled clinical trials integrating 3512 participants were assessed. Overall, the pooled eradication rates of tailored groups were higher than those of empiric ones (intention-to-treat: RR = 1.16, 95% CI 1.10–1.22; preprotocol: RR = 1.14, 95% CI 1.08–1.21). In subgroup analysis, tailored therapy was superior to 7-day standard triple therapy (RR = 1.22, 95% CI 1.16–1.29) and bismuth-quadruple therapy (RR = 1.14, 95% CI 1.07–1.22) on eradication rates; first-line tailored therapy achieved higher eradication rates than first-line empiric regimens (pooled RR = 1.18, 95% CI 1.14–1.22), whereas tailored rescue regimen showed no difference with empirical ones (pooled RR = 1.16, 95% CI 0.96–1.39). Moreover, among different tailored designs, susceptibility-guided tailored therapy obtained higher eradication rates than empiric groups, independent of CYP2C19 genotype detection (with CYP: RR = 1.16, 95% CI 1.09–1.23; without CYP: RR = 1.14, 95% CI 1.01–1.28). Both molecular test-based and culture-based tailored groups were better on eradication rates than empiric regimens (molecular: RR = 1.23, 95% CI 1.11–1.35; culture: RR = 1.13, 95% CI 1.06–1.20).

Compared with empiric chosen treatments, tailored therapy is a better alternative for *H pylori* eradication.

INTRODUCTION

Since the discovery of *Helicobacter pylori* in 1982, research has been conducted over decades to explore the optimal eradication strategy.1–3 According to Kyoto global consensus report, *H pylori*-induced gastritis is classified into the category of infectious disease.4 However, the strategy of *H pylori* eradication is difficult to follow the common treatment protocols of most infectious diseases. This is largely ascribed to the unavailability of susceptibility testing for *H pylori* in routine clinical laboratory.1,5 Consequently, clinicians usually choose antibiotics empirically in an eradication therapy. Nevertheless, due to the growing tendency of antimicrobial resistance, the unconditional use of standard triple therapy is reported to be obsolete.6,7 Although other empiric regimens (e.g., bismuth-quadruple therapy [BQT], sequential therapy) are currently recommended, the effectiveness is still controversial. Actually, many individual factors may compromise the eradication success. These factors include antibiotic resistance pattern, individual genetic morphology, past history of medicine, tolerance of treatment, and also personal compliance.1,2 Hence, a precisely targeted regimen is allowed for *H pylori* eradication. Under this situation, there is an emerging trend towards an individualized eradication therapy which is aimed to achieve the optimal drug responses.5,7,8

During the past decade, the pretreatment susceptibility testing was performed by some studies to avoid antibiotic resistance.6 There are mainly 2 types of test methodologies: genotype detection and phenotype identification. The genotypic detection refers to molecular tests (e.g., real-time PCR, fluorescent in situ hybridization) by using samples such as stools and gastric biopsy specimens. The phenotypic identification stands for traditional antimicrobial susceptibility testing (e.g., E-test, agar dilution method) through culture of *H pylori* strains.9,10
However, antibiotic resistance is not the only factor to affect the drug effectiveness. Recently, proton pump inhibitor (PPI), whose metabolism depends on CYP2C19-catalyzed reaction, has also been reported to exert influence on therapeutic efficacies. Consequently, new personalized therapies are emerging by adding the detection of CYP2C19 genotype within a tailored design.

Currently, there are merely a few publications of literature reviews for assessing the efficacy of tailored therapies. Therefore, we conducted a meta-analysis to compare tailored eradication therapy with empirical regimens on therapeutic effectiveness of H pylori eradication.

METHODS

Information Sources and Search Strategy
This meta-analysis was conducted in accordance with PRISMA guidelines. Following the search strategy, one reviewer (CH) conducted a literature search on PubMed, EMBASE, and MEDLINE database by using the following terms: (((((((tailored therapy) OR tailored eradication) OR tailored treatment)) OR (((personalized eradication) OR personalized therapy) OR personalized treatment)) OR (((pretreatment susceptibility tests) OR susceptibility-based treatment) OR susceptibility-guided)) OR (((cyp2c19 genotype) OR cyp2c19 polymorphism) OR genetic polymorphism) OR (((IL-1) OR interleukin-1) OR virulence factors) OR BMI)) AND (((Helicobacter pylori) OR H. pylori) OR H. pylori)). The consent procedure and study protocol were approved by the Medical Institutional Ethical Committee of first affiliated hospital of Nanjing Medical University.

Eligibility Criteria
All original articles, published up to October 2015, which compared the eradication efficacy between tailored and empirical regimens, were included in this meta-analysis. All studies were published as full articles. The abstracts of these articles were carefully screened by 2 independent reviewers (CH and DYN). Clinical controlled trials were primarily considered. Retrospective studies, case reports, and also other clinical trials without controlled therapeutic groups were all excluded. In addition, the eligible studies should include the accessible data of successful eradication rates in both tailored and empirical groups. Patients meeting the following criteria were excluded: history of medicine within previous 4 weeks; previous history of gastrointestinal malignancy; previous gastric or esophageal surgery histories; severe infectious diseases or systemic disorders, such as severe organ dysfunction; and alcohol abuse or pregnancy or under lactation.

Data Collection Process
The first reviewer (CH) read the titles and abstracts of each article and then obtained preliminarily eligible studies. The second reviewer (DYN) screened these papers based on eligibility criteria. Reference lists of relevant publications were checked for potentially eligible studies. Contacts were made by e-mails to the authors for any requirements of missing data among eligible studies. Discrepancies were resolved by consensus between the 2 reviewers. Data extraction process was conducted by the first reviewer (CH) and then a further check was made by 3 other reviewers (ZXY, LBT, and LSY).

Data Items
The following information was extracted in each study: baseline demographics variables (year and country of publication, study design, mean age, sex, and sample size); diagnostic tests of H pylori infection; treatment regimens of both tailored and control groups (regimen, dosage, and dose interval); the number of patients in each group who are successfully treated; the eradication rates in both tailored and control arms, side effects during or after eradication (if any trial evaluated); and the cost of each therapy (if any trial calculated).

Risk of Bias in Individual Studies
The Cochrane Tool of Bias was applied to ascertain the validity of eligible randomized trials. All studies were evaluated by 2 independent reviewers (CH and ZXY) with adequate reliability in determining the following domains: the adequacy of randomization and concealment of allocation, blinding of participants, personnel and outcome assessors, the extent of loss to follow-up, the assessment of selective outcome reporting, and other sources of bias. Discrepancies were resolved by consensus between the 2 reviewers (Figure 2A and B).

Risk of Bias Across Studies
Statistical heterogeneity across the studies was assessed visually with Begg funnel plot (Figure 5). Harbord modified test was also applied.

Statistical Analyses
The meta-analyses were performed by computing relative risks (RRs) using random-effects model. Quantitative analyses were performed on an intention-to-treat (ITT) and preprotocol (PP) basis, with RR and related 95% confidence intervals (CIs) for each. Meta-regression and subgroup analysis were performed for additional analysis.

RESULTS

Study Selection and Characteristics
Figure 1 details the procedure of study selection in the flow chart. Thirteen studies13–25 were qualified in this meta-analysis. Tables 1 and 2 summarize the baseline characteristics. A total 3512 participants received treatments of H pylori eradication. Among them, 1295 participants received tailored regimens,

FIGURE 1. Flow chart of studies.
whereas 2217 received empirical treatments. Ten studies were randomized control trials \textsuperscript{13–18,20,22–24} and 3 were nonrandomized controlled clinical trials \textsuperscript{19,21,25} In terms of areas, 7 studies \textsuperscript{13,18,20–23} were reported in Asia and 6 studies \textsuperscript{14–17,19,24} were reported from Europe. Moreover, 3 studies \textsuperscript{18,23,25} set 2 different control groups, respectively, which were labeled as group a and b in our study (e.g., Lee a and Lee b). The quality of publication evaluated was of medium-to-low quality evidence and only 1 study had low risk of bias. Both Begg funnel plot ($P = 0.893$) and Harbord modified test ($P = 0.0089$) indicate no evidence of heterogeneity across the studies (Figure 5).

### Eradication Rate

In 13 trials, data of eradication rates were available in 3246 participants (266 were lost to follow-up). The pooled RR of ITT in tailored groups over control groups was 1.16 (95% CI 1.11–1.22) and the pooled RR of PP was 1.16 (95% CI 1.10–1.22), both with the evidence of high heterogeneity (ITT: $I^2 = 57.1\%$, $P = 0.003$; PP: $I^2 = 73.2\%$, $P = 0.000$) (Figure 3A and B). Meta-regression demonstrates no significant difference of study design ($P = 0.345$) and area ($P = 0.600$), pediatric/adult population ($P = 0.641$), and sex ($P = 0.577$).

### Subgroup Analysis

Tailored therapy shows its superiority over empirical treatment in both Asia (pooled RR = 1.18, 95% CI 1.11–1.25) and Europe (pooled RR = 1.14, 95% CI 1.03–1.25).

### Types of Tailored Regimens

Pretreatment susceptibility testing and CYP2C19 polymorphisms were 2 main determinants for designing tailored therapy. Ten tailored regimens \textsuperscript{14–17,19,21–25} were designed according to pretreatment susceptibility testing (pooled RR = 1.17, 95% CI 1.11–1.24). Three other studies \textsuperscript{13,18,20} advanced their susceptibility-guided therapy by additionally adjusting their PPI administration (either by dosage adjustments or by changing drugs) on the basis of CYP2C19 polymorphism (pooled RR = 1.14, 95% CI 1.01–1.28). The analytical results indicate that both types of tailored therapy are better than empirical treatments in achieving higher eradication rates (Figure 4A).
| Authors          | Area                | Study Design | Patients/Lines | Population Size (Tailored/Empiric) | Diagnostic Methods | Tailored Determinants | Pretreatment Susceptibility Test |
|------------------|---------------------|--------------|----------------|-------------------------------------|--------------------|-----------------------|----------------------------------|
| Kawai et al      | Japan               | RCT          | Adults/first-line | 70 (35/35)                          | 13C-UBT + 13C-UBT  (6–8 wk later) | Susceptibility test       | PCR (stool)                      |
| Romano et al     | Italy               | RCT          | Adults/first-line | 150 (75/75)                         | 13C-UBT/serology + 13C-UBT (12 wk later) | Susceptibility test       | E-test                           |
| Neri et al       | Italy               | RCT          | Adults/first-line | 242 (121/121)                       | RUT/histology/culture + 13C-UBT (8 wk later) | Susceptibility test       | E-test                           |
| Tomacchio et al  | Italy               | RCT          | Adults/first-line | 109 (53/56)                         | RUT/culture/13C-UBT + 13C-UBT (1 mo later) | Susceptibility test       | Agar dilution method              |
| Bontems et al    | Belgium + France + Italy | RCT          | Children/second-line | 165 (82/83)                        | Histology and culture + 13C-UBT (8 wk later) | Susceptibility test       | E-test                           |
| Lee et al        | Korea               | RCT          | Adults/first-line | 834 (218/616)                       | Histology + 13C-UBT (6–8 wk later) | Susceptibility test       | PCR (gastric biopsy)             |
| Street et al     | Italy               | CCT          | Children/first-line | 150 (75/75)                         | Endoscopic appearance /RUT/histology/ culture + the same (6 mo later) | Susceptibility test       | E-test                           |
| Furay et al      | Japan               | RCT          | Adults/first-line | 300 (150/150)                       | RUT + RUT and 13C-UBT (1 mo later) | Susceptibility test + CYP   | PCR (gastric biopsy)             |
| Yahav et al      | Israel              | CCT          | Adults/nonfirst-line | 96 (49/49)                         | RUT and histology + 13C-UBT (6 wk later) | Susceptibility test       | E-test                           |
| Miwa et al       | Japan               | RCT          | Adults/second-line | 77 (38/39)                          | ≥ Two (+) tests + 13C-UBT (6–8 wk after) | Susceptibility test + CYP | Dry plate method                 |
| Zhou et al       | China               | RCT          | Adults/first-line | 1080 (318/700)                      | RUT and culture + 13C-UBT (4–12 wk after) | Susceptibility test + CYP | E-test                           |
| Romano et al     | Italy               | RCT          | Adults/first-line | 80 (40/40)                          | RUT and culture + 13C-UBT (12 wk later) | Susceptibility test       | E-test                           |
| Kwon et al       | South Korea         | CCT          | Adults/second-line | 219 (41/178)                        | 13C-UBT/≥ one invasive tests (RUT, histology, culture) | Susceptibility test       | Agar dilution method              |

13C-UBT = 13C urea breath test, CCT = controlled clinical trial, CYP = CYP2C19 polymorphism detection; RCT = randomized control trial, RUT = rapid urease test.
| Authors        | Tailored Regimens                                                                 | Empiric Controls                                                                 | % Eradication Rate of Tailored (No. Patients) | % Eradication Rate of Control (No. Patients) |
|---------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------|
| Kawai et al   | CAM-s: LPZ 30 mg bid + AMP 750 mg bid + CAM 400 mg bid, 7 d; CAM-r: RPZ 10 mg bid + AMP 750 mg bid + MET 250 mg bid, 7 d | LPZ 30 mg bid + AMP 750 mg bid + CAM 400 mg bid, 7d | ITT 94.5% (33/35) PP 94.5% (33/35) | ITT 71.4% (25/35) PP 78.1% (25/34) |
| Romano et al  | CAM-s and MET-s: OPZ 20 mg bid + CAM 500 mg bid + MET 500 mg bid, 7d; CAM-r: OPZ 20 mg bid + AMP 1 g bid + MET 500 mg bid, 7d; MET-r: OPZ 20 mg bid + AMP 1 g bid + CAM 500 mg bid, 7d | OPZ 20 mg bid + CAM 500 mg bid + MET 500 mg bid, 7d | ITT 94.6% (71/75) PP 97.3% (71/73) | ITT 77.3% (58/75) PP 79.4% (58/73) |
| Neri et al    | CLM-r: OPZ 20 mg bid + CAM 500 mg bid + AMP 1 g bid, 7 d ranitidine bismuth citrate 400 mg bid + CAM 500 mg bid + TIN 500 mg bid, 7d; TIN-r: OPZ 20 mg bid + CAM 500 mg bid + AMP 1 g bid, 7d | OPZ 20 mg bid + CAM 500 mg bid + AMP 1 g bid, 7d ranitidine bismuth citrate 400 mg bid + CAM 500 mg bid + TIN 500 mg bid, 7d | ITT 94.6% (71/75) PP 97.3% (71/73) | ITT 77.3% (58/75) PP 79.4% (58/73) |
| Tonacchio et al | CAM-s and TIN-s: OPZ 20 mg bid + TIN 500 mg bid + CAM 500 mg bid, 10 d; CAM-r: OPZ 20 mg bid + TIN 500 mg bid + AMP 1 g bid, 10d; TIN-r: OPZ 20 mg bid + AMP 1 g bid + CAM 500 mg bid, 10 d | OPZ 20 mg bid + TIN 500 mg bid + CAM 500 mg bid, 10d | ITT 91% (48/53) PP 98% (52/58) | ITT 75% (42/56) PP 81% (52/58) |
| Bontems et al | CAM-s: OPZ + AMP + CAM; CAM-r and MET-s: OPZ + AMP + MET (dosage not mentioned) | The first 5 days: OPZ (10 mg if <30 kg or 20 mg bid if >30 kg) bid + AMP 25 mg/kg bid; the followed days: OPZ + CAM (7.5 mg/kg, max: 1 g/d) bid + MET (10 mg/kg, max: 1.5 g/d) bid | ITT 71.9% (59/82) PP 80.8% (59/73) | ITT 81.9% (68/83) PP 88.3% (68/77) |
| Lee et al     | CAM-s: AMP 1000 mg bid + RPZ 20 mg bid + CAM 500 mg bid, 7d; CAM-r: AMP 1000 mg bid + RPZ 20 mg bid + MET 500 mg tid, 7d | Group a: AMP + RPZ + CAM, 7d Group b: AMP + RPZ + MET, 7d (dosage not mentioned) | ITT 80.7% (176/218) PP 91.2% (176/193) | ITT 69.5% (214/308) PP 75.9% (214/282); ITT 71.1% (219/308) PP 79.1% (219/277) |
| Street et al  | Not mentioned specifically                                                        | Ranitidine (6 mg/kg/d, bid)/OPZ (1 mg/kg/d, qd) + AMP (50 mg/kg/d) + CAM (30 mg/kg/d), 8d | ITT 96% (72/75) PP 99% (72/73) | ITT 81% (61/75) PP 88% (65/75) |
| Furuta et al  | CAM-s: PPI (RM: LPZ 30 mg tid, IM: LPZ 15 mg tid, PM: LPZ 15 mg bid) + CAM 200 mg tid + AMP 500 mg tid, 7 d; CAM-r:LPZ 30 mg qid, IM: LPZ 15 mg qid, PM: LPZ 15 mg bid) + AMP 500 mg qid, 14 d | LPZ 30 mg bid + CAM 400 mg bid +AMP 750 mg bid, 7d | ITT 96% (144/150) PP 96.6% (144/149) | ITT 70% (105/150) PP 72.9% (105/144) |
| Yahav et al   | CAM-s:OPZ 20 mg bid + CAM 500 mg bid + AMP 1 g bid, 7 d; CAM-r and MET-s: OPZ 20 mg bid + MET 500 mg bid + AMP 1 g bid (TEC 500 mg qid, if allergic), 7 d; CAM-r and MET-r: OPZ 20 mg bid + AMP 1 g bid + TEC 500 mg qid + colloidal bismuth subcitrate 120 mg qid, 7d | Regimen1: OPZ + AMP + CAM/ MET, 7d Regimen2: OPZ + Bismuth + MET + TEC, 7d (dosage not mentioned) | ITT 86% (42/49) PP 88% (42/49) | ITT 63% (31/49) PP 63% (31/49) |
| Authors         | Tailored Regimens                                                                 | Empiric Controls                          | Eradication Rate of Tailored (No. Patients) | Eradication Rate of Control (No. Patients) |
|-----------------|-----------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|------------------------------------------|
| Miwa et al      | CAM-s: LPZ 30 mg bid + CAM 200 mg bid + AMP 750 mg bid, 10d; CAM-r and MET-s: LPZ 30 mg bid + MET 250 mg bid + AMP 750 mg bid, 10d; CAM-r and MET-r: OPZ 20–60 mg bid + CAM 200 mg bid + AMP 1000 mg bid, 14d | LPZ 30 mg bid + MET 250 mg bid + AMP 750 mg bid, 10d | ITT 81.6% (31/38) PP 83.3% (30/36)      | ITT 92.4% (36/39) PP 94.7% (36/38)      |
| Zhou et al      | CAM-s: EM: RPZ 10 mg bid + AMP 1000 mg bid + CAM 500 mg bid, PM or HM: EPZ 20 mg bid + AMP + 1000 mg bid CAM 500 mg bid, 10 d; CAM-r: EM: RPZ 10 mg bid + AMP 1000 mg tid + TIN 500 mg tid, PM or PM: EPZ 20 mg bid, 10 d | Group a: EPZ 20 mg bid + AMP 1000 mg bid + CAM 500 mg bid + bismuth potassium citrate 220 mg bid, 10 d; group b: EPZ 20 mg bid + AMP 1000 mg bid + CAM 500 mg bid + TIN 500 mg bid, 10 d | ITT 88.7% (282/318) PP 99.3% (278/298) | ITT 87.4% (271/350) PP 87.00% (261/300); ITT 78.3% (274/350) PP 87.4% (263/301) |
| Romano et al    | CAM-s and MET-s: OPZ 20 mg bid + CAM 500 mg bid + MET 500 mg bid, 7d; CAM-r: OPZ 20 mg bid + AMP 1 g bid + MET 500 mg bid, 7d; MET-r: OPZ 20 mg bid + AMP 1 g bid + CAM 500 mg bid, 7d | OPZ 20 mg bid + CAM 500 mg bid + MET 500 mg bid, 7d | ITT 95.0% (38/40) PP 97.4% (38/39)      | ITT 77.5% (31/40) PP 79.5% (31/39)      |
| Kwon et al      | MOX-r: EBMT regimen (EPZ 40 mg bid + bismuthate 300 mg qid + MET 500 mg tid + TEC 500 mg qid, 14d); MET-r: MEA regimen (MOX 400 mg qd + EPZ 40 mg bid + AMP 1 g bid, 14d); MET-r and MOX-r: either 14-d EBMT or MEA regimen by considering the cost, complexity and side effects | Group a: EPZ 40 mg bid, bismuthate 300 mg qid + MET 500 mg tid + TEC 500 mg qid, 14d; Group b: MOX 400 mg qd + EPZ 40 mg bid + AMP 1 g bid, 14d | ITT 90.2% (37/41) PP 100% (37/37)       | ITT 75.3% (67/89) PP 79.8% (67/84); ITT 70.8% (63/89) PP 72.4% (63/87) |

AMP = amoxicillin, CAM = clarithromycin, CAM-r = clarithromycin resistant, CAM-s = clarithromycin sensitive, EPZ = esomeprazole, het EM = heterozygous extensive metabolizer, hom EM = homozygous extensive metabolizer, LPZ = lansoprazole, MET = metronidazole, MET-r = metronidazole resistant, MET-s = metronidazole sensitive, MOX = moxifloxacin, MOX-r = moxifloxacin resistant, OPZ = omeprazole, PM = poor metabolizer, RPZ = rabeprazole, TEC = tetracycline, TIN = tinidazole, TIN-r = tinidazole resistant, TIN-s = tinidazole sensitive.
Methods of Antibiotic Susceptibility Testing

All 13 tailored trials applied pretreatment susceptibility tests for detecting individual antibiotic resistance patterns. In 3 studies, genetic resistance of antibiotics were detected by molecular methods (pooled RR = 1.23, 95% CI 1.11–1.35). Ten other studies performed traditional culture-based tests in detecting phenotype resistance patterns (pooled RR = 1.14, 95% CI 1.08–1.21); the pooled results demonstrate that susceptibility-guided tailored therapies achieved higher eradication rates than empirical regimens by using either molecular-based or traditional culture-based test (Figure 4B).

First-Line and Nonfirst-Line Tailored Therapy

Nine studies designed first-line tailored therapy, whereas 3 studies applied salvage tailored therapy. One trial performed tailored regimen as both first-line and rescue therapy. The pooled results indicate that first-line tailored therapy obtained higher eradication rates than first-line empirical regimens (pooled RR = 1.18, 95% CI 1.14–1.22). There is no significant difference in eradication rates between tailored rescue regimen and empirical rescue ones (pooled RR = 1.16, 95% CI 0.96–1.39) (Figure 4C).
Different Empiric Regimens

In total, there were 5 different empiric regimens in 16 groups. In 7 studies,\textsuperscript{13,14,18–21,24} participants from empiric groups received 7-day standard triple therapy. Two trials applied the 10-day therapeutic duration. BQT was used in 3 trials\textsuperscript{15,23,25} (Zhou et al group a and YH Kwon et al. group a). Two studies\textsuperscript{17,23} (Zhou et al, group a) selected sequential therapy, and 1 trial applied 14-day moxifloxacin-containing triple regimen\textsuperscript{25} (Kwon et al, group b). These results show that tailored therapy achieved higher eradication when compared with 7-day standard triple therapy (pooled RR = 1.22, 95% CI 1.16–1.29), BQT (pooled RR = 1.15, 95% CI 1.08–1.22), and 14-day moxifloxacin-containing triple regimen (pooled RR = 1.27, 95% CI 1.08–1.51). Unexpectedly, tailored therapy shows no significant differences in eradication rates with 10-day-triple therapy (pooled RR = 1.03, 95% CI 0.76–1.41) and sequential therapy (pooled RR = 1.01, 95% CI 0.79–1.30) (Figure 4D).

DISCUSSION

Summary of Evidence

This is the first meta-analysis in evaluating the potential therapeutic efficacy of tailored therapy in \textit{H pylori} eradication. Our meta-analysis has 5 principal findings: overall, tailored therapy was more efficacious than empiric one; higher eradication rates were achieved than those of empiric regimens in a susceptibility-based tailored therapies, irrespective of CYP2C19 genotype polymorphism; both culture-based and molecular-based tailored therapy obtained good therapeutic efficacies; tailored therapy achieved better effectiveness than 7-day standard triple therapy and BQT; the first-line tailored therapy is better than empiric treatments, whereas tailored rescue therapy did not perform better than empiric ones.

Here, we defined tailored therapy as a precisely targeted \textit{H pylori} eradication therapy which emphasizes on predicting individual drug responses before treatment.\textsuperscript{1,6–8,13–25} Actually, tailored therapies are diversified. Different adjectives have been used to describe it as tailored, personalized, individualized, culture-based, pharmacogenetic-based, and susceptibility-guided\textsuperscript{13–25} This attributes to the fact that multiple factors will affect the final eradication success.\textsuperscript{1,6} These factors include antibiotic resistance, dosing of acid inhibitory drugs, genotypes of drug-metabolizing enzymes, drug transporters, inflammatory cytokines (i.e., interleukin [IL]-1β), one’s past medical history, treatment tolerance, and also personal compliance.\textsuperscript{6,11,26} Rationally, an eradication treatment should be evidence-based.\textsuperscript{8} Since the drug response varies from person to person, patients will benefit from an individualized treatment as precisely as possible. However, when considering the cost and feasibility, it is difficult to include all individual factors into a tailored design. Hence, it is better to identify the main influential factors as the major tailored determinants.

Antibiotic resistance is considered to be one of the main reasons for eradication failure.\textsuperscript{27–29} Thus, it is considered as a major tailored determinant by most tailored trials. Importantly, our result challenges the necessity of performing traditional susceptibility tests within a tailored therapy. Although traditional methodologies are useful in determining phenotypic resistance patterns of antibiotics,\textsuperscript{10} they are rarely available in routine clinical practice. There are several reasons: first, it is fastidious and time-consuming to grow \textit{H pylori} in culture;\textsuperscript{10} second, there is no standard method for the interpretation of susceptibility\textsuperscript{17}; and third, the in vitro test might not reflect the actual levels of antibiotics in the gastric lumen in which there is possible pH influence on antimicrobial activity.\textsuperscript{21} Consequently, such tests are usually considered within a salvage therapy after multiple treatment failures.\textsuperscript{1,3–27} Currently, new molecular tests begin to emerge, allowing clinicians to obtain evidence of antibiotic resistance without culture procedures. Some publications reported that therapies tailored by molecular tests achieved higher success rates than those by traditional culture-based tests.\textsuperscript{26–28} Actually, molecular tests are advantageous: firstly, they have simple procedures and are time-saving; moreover, clinicians can easily obtain stool samples or gastric specimens through endoscopic biopsies.\textsuperscript{10} Hence, it is worthwhile to further estimate the value of molecular tests for antimicrobial resistance.

The second tailored determinant is the individual CYP2C19 genotype. In this study, the role of CYP2C19 polymorphisms detection is challenged in a susceptibility-guided tailored therapy. A literature review of tailored eradication therapy indicates that a tailored treatment designed according to pharmacogenomics and antimicrobial susceptibility achieves an eradication rate exceeding 95%, irrespective of eradication history, and overcomes differences among CYP2C19 genotypes.\textsuperscript{12} However, our results show that CYP2C19 detection may be less clinically significant when antibiotic resistance has already been taken into account within a tailored design. Although rapid metabolizers (RMs) are reported to have decreased eradication rates than intermediate/ poor ones,\textsuperscript{11,12} the influence of CYP genotype in RM is probably overcome by increasing PPI dosing or by administrating advanced PPI such as rabeprazole or esomeprazole, which rarely metabolizes through CYP2C19 pathway.\textsuperscript{11} Considering that PPI administration varies in trials, more randomized clinical trials are needed for evaluating the role of CYP2C19 detection on improving eradication rate in tailored therapies.

The next assessment in our meta-analysis is the efficacy of tailored therapies as the first-line or rescue regimens. Currently, tailored therapy is not routinely applied as a first-line eradication treatment.\textsuperscript{1} According to the Maastricht Consensus Conferences, the antibiotic susceptibility testing before antibiotic therapy is suggested after the failure of second-line treatment.\textsuperscript{28} Nevertheless, in our analysis, better eradication rates were achieved in most first-line tailored regimens than in the empiric groups, indicating the potential value of tailored regimen as an
alternative first-line eradication choice. However, when it comes to rescue tailored therapy, the advantage is not so obvious. Here, the pooled results are mainly influenced by 1 trial conducted by Miwa et al concluding that susceptibility testing is not necessarily required before second-line therapy if the first-line treatment has been performed by PPI/AC regimens. Since pretreatment susceptibility tests would help overcome antibiotic resistance, tailored therapy is superior to standard triple therapy in eradication rate. However, the advantage of tailored therapy is undermined when the duration of triple therapy is prolonged to 10 days. The explanation is probably that increasing duration will increase the drug effectiveness to overcome antibiotic resistance in standard triple therapy. In this sense, the advantages of tailored therapy are still controversial. Meanwhile, we discovered that tailored therapy is superior to BQT in eradication improvement. The possible explanation is that BQT is advantageous by partially overcoming the resistance to major antibiotics such as clarithromycin or levofloxacin, but it is less targeted when compared with tailored therapy in getting precise evidence of antibiotic resistance patterns on individual levels. Therefore, for its evidence-based characteristics, tailored therapy is better than BQT in individual therapeutic precision.

Limitations

There are several limitations in this meta-analysis. Firstly, we are unable to analyze the side effects for further investigating the feasibility of tailored regimens. Most of the trials merely focused on eradication rates, and only 4 trials provided data of side effects. Secondly, we failed to include the cost in both groups. Although 2 trials demonstrated that tailored therapy is more cost-saving than standard triple therapy (saving $5 and $12 on average, respectively), there were still insufficient data to show whether tailored therapy could be more cost effective than other popular empirical regimens. Thirdly, the 3 trials were not randomized, which might have affected the validity of the overall findings. Furthermore, due to the small sample sizes of clinical trials included in our meta-analysis, large-scale randomized clinical trials are urgently warranted with regards to comparison of therapeutic efficacy between tailored regimens and different empiric ones.

CONCLUSIONS

In summary, compared with empiric chosen regimen, tailored therapy is a better alternative for *H pylori* eradication. It is clinically significant to promote broader assessments of tailored therapy compared with different empirical treatments worldwide. We also suggest further research regarding more therapeutic innovations customized for specific individuals with *H pylori* infection.

REFERENCES

1. Rimbara E, Fischbach LA, Graham DY, et al. Optimal therapy for *Helicobacter pylori* infections. *Nat Rev Gastroenterol Hepatol*. 2011;8:79–88.
2. Graham DY, Lee YC, Wu SM, et al. Rational *Helicobacter pylori* therapy: evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol*. 2014;12:177–186.
3. Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut*. 2010;59:1143–1153.
4. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on *Helicobacter pylori* gastritis. *Gut*. 2015;64:1353–1367.
5. Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of *Helicobacter pylori* infection: meeting the challenge of antimicrobial resistance. *World J Gastroenterol*. 2014;20:9898–9911.
6. Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate *Helicobacter pylori* infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. *Expert Opin Pharmacother*. 2007;8:2701–2717.
7. Lewis LD. Personalized drug therapy: the genome, the chip and the physician. *Br J Clin Pharmacol*. 2005;60:1–4.
8. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature*. 2004;429:464–468.
9. Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother*. 2013;68:450–456.
10. Nishizawa T, Suzuki H. Mechanisms of *Helicobacter pylori* antibiotic resistance and molecular testing. *Front Mol Biosci*. 2014;1:19.
11. Zhao FJ, Wang J, Yang YM, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of *H. pylori* eradication proton pump inhibitor-based triple therapy for *Helicobacter pylori* eradication: a meta-analysis. *Helicobacter*. 2008;13:532–541.
12. Sugimoto M, Furuta T, et al. Efficacy of tailored *Helicobacter pylori* eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. *World J Gastroenterol*. 2014;20:6400–6411.
13. Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on local *Helicobacter pylori* clarithromycin sensitivities. *J Gastroenterol Hepatol*. 2008;23(Suppl 2):S171–174.
14. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of *Helicobacter pylori*. *Clin Gastroenterol Hepatol*. 2003;1:273–278.
15. Neri M, Milano A, Laterza F, et al. Role of antibiotic sensitivity testing before first-line *Helicobacter pylori* eradication treatments. *Aliment Pharmacol Ther*. 2003;18:821–827.
16. Toracchio S, Cellini L, Dicamil L, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in *Helicobacter pylori* eradication. *Aliment Pharmacol Ther*. 2000;14:1639–1643.
17. Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for *Helicobacter pylori* infection in children. *J Pediatr Gastroenterol Nutr*. 2011;53:646–650.
18. Lee HJ, Kim JI, Cheung DY, et al. Eradication of *Helicobacter pylori* according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. *J Infect Dis*. 2011;208:1123–1130.
19. Street ME, Caruana P, CaVarelli C, et al. Antibiotic resistance and antibiotic sensitivity-based treatment in *Helicobacter pylori* eradication: advantages and outcome. *Arch Dis Child*. 2001;84:419–422.
20. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of *H. pylori*. *Clin Pharmacol Ther*. 2007;81:521–528.
21. Yahav J, Samra Z, Niv Y, et al. Susceptibility-guided vs. empiric retreatment of *Helicobacter pylori* infection after treatment failure. *Dig Dis Sci*. 2005;51:2316–2321.
22. Miwa H, Magahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther. 2003;17:1545–1551.

23. Zhou LY, Zhang JZ, Song ZQ, et al. Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: a randomized trial. Helicobacter. 2015 doi: 10.1111/hel.12242.

24. Romano M, Iovene MR, Montella F, et al. Pretreatment antimicrobial susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol. 2000;95:3317–3318.

25. Kwon HY, Kim N, Lee JY, et al. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scand J Gastroenterol. 2015;9:1–7.

26. Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:1639–1643.

27. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001.

28. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664.

29. Giorgio F, Principi M, DeFrancesco V, et al. Primary clarithromycin resistance to Helicobacter pylori: is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol. 2013;4:43–46.

30. Kim JM, Kim JS, Jung HC, et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004;48:4843–4847.

31. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol. 2001;36:690–700.

32. Gisbert JP, Pajares JM. Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047–1057.

33. Ford AC. First-line eradication therapy for Helicobacter pylori: time for a change? Gastroenterology. 2013;144:652–653.

34. Xie Lu, et al. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2014;20:1–10.

35. Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.

36. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343e57.